Eric Daniels

Corporate Officer/Principal presso KIORA PHARMACEUTICALS, INC.

Patrimonio netto: 42 288 $ in data 30/04/2024

51 anni

Consumer Services

Health Technology

Commercial Services

Posizioni attive di Eric Daniels

Società	Posizione	Inizio	Fine
KIORA PHARMACEUTICALS, INC.	Corporate Officer/Principal	21/10/2021	-
Okogen, Inc. Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA.	Direttore/Membro del Consiglio	-	-
	Fondatore	-	-
Bayon Therapeutics, Inc.	Direttore/Membro del Consiglio	-	-
Bayon Therapeutics, Inc.	Fondatore	-	-

Società	Posizione	Inizio	Fine
OccuRx Pty Ltd OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.	Amministratore Delegato	-	-

University of California, Berkeley	Undergraduate Degree
David Geffen School of Medicine	Doctorate Degree
Anderson School of Management	Masters Business Admin

Distribuzione geografica

Stati Uniti	7
Australia	2

Posizioni

Director/Board Member	2
Founder	2
Corporate Officer/Principal	1

Settori

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
KIORA PHARMACEUTICALS, INC.	Health Technology

Aziende private	3
Okogen, Inc. Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA.	Commercial Services
OccuRx Pty Ltd OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia.	Health Technology
Bayon Therapeutics, Inc.